MCID: ADN018
MIFTS: 64

Adenoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Adenoma

MalaCards integrated aliases for Adenoma:

Name: Adenoma 12 76 55 15 73
Acinar Cell Adenoma 12 73
Adenomas 12 15
Acinic Cell Adenoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:657
MeSH 44 D000236
NCIt 50 C2855 C4196
SNOMED-CT 68 32048006 79041005

Summaries for Adenoma

Disease Ontology : 12 A cell type benign neoplasm that is composed_of epithelial tissue in which tumor cells form glands or glandlike structures.

MalaCards based summary : Adenoma, also known as acinar cell adenoma, is related to pituitary adenoma, prolactin-secreting and pleomorphic adenoma. An important gene associated with Adenoma is PLAG1 (PLAG1 Zinc Finger), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Gastric cancer. The drugs Rabeprazole and Erythromycin have been mentioned in the context of this disorder. Affiliated tissues include pituitary, colon and thyroid, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 76 An adenoma (from Greek αδένα�?, adeno-, "gland" + -�?μα, -oma, "tumor") (/�?ædɪ�?no�?m�?/; plural... more...

Related Diseases for Adenoma

Diseases related to Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 942)
# Related Disease Score Top Affiliating Genes
1 pituitary adenoma, prolactin-secreting 34.0 AIP GNAS MEN1 PRL
2 pleomorphic adenoma 34.0 PLAG1 PLAGL1 PLAGL2
3 parathyroid adenoma 33.9 CCND1 CDC73 MEN1 RET
4 sebaceous adenoma 33.8 MLH1 MSH2
5 colorectal adenoma 33.8 APC CTNNB1 KRAS MLH1 MSH2
6 growth hormone secreting pituitary adenoma 33.7 AIP GNAS PRL
7 periampullary adenoma 33.5 APC KRAS
8 silent pituitary adenoma 33.4 AIP MEN1
9 null pituitary adenoma 33.2 AIP MEN1
10 acromegaly 33.0 AIP GNAS MEN1 PRL
11 polyposis syndrome, hereditary mixed, 1 32.9 APC MLH1
12 hyperparathyroidism 1 32.7 CDC73 MEN1
13 colorectal cancer 32.4 APC CCND1 CTNNB1 GNAS KRAS MLH1
14 hyperparathyroidism 2 with jaw tumors 32.4 CCND1 CDC73 MEN1 RET
15 mutyh-associated polyposis 32.3 APC KRAS SMAD4
16 endometrial adenocarcinoma 32.3 CTNNB1 KRAS MLH1
17 parathyroid carcinoma 32.3 CCND1 CDC73 MEN1 RET
18 multiple endocrine neoplasia, type i 32.2 CDC73 GNAS MEN1 PRL RET
19 mismatch repair cancer syndrome 32.1 APC CTNNB1 MLH1 MSH2
20 multiple endocrine neoplasia, type iia 32.1 CDC73 MEN1 RET
21 familial adenomatous polyposis 32.0 APC CCND1 CTNNB1 KRAS MLH1 MSH2
22 familial adenomatous polyposis 1 32.0 APC CTNNB1
23 hyperparathyroidism 31.3 CDC73 MEN1 RET
24 primary hyperparathyroidism 31.0 CCND1 CDC73 MEN1 PRL RET
25 adenocarcinoma 30.9 APC CCND1 CTNNB1 GNAS KRAS MLH1
26 hyperthyroidism 30.7 GNAS PRL TSHR
27 pituitary tumors 30.6 AIP GNAS MEN1 PRL
28 peutz-jeghers syndrome 30.6 APC CTNNB1 SMAD4
29 mccune-albright syndrome 30.5 APC GNAS PRL
30 carney complex variant 30.5 AIP GNAS MEN1
31 lynch syndrome 30.4 APC CCND1 CTNNB1 KRAS MLH1 MSH2
32 hypothyroidism 30.4 GNAS PRL RET TSHR
33 thyroid cancer 30.3 APC CCND1 CTNNB1 GNAS KRAS RET
34 cholangiocarcinoma 30.2 APC CCND1 CTNNB1 KRAS SMAD4
35 colon adenocarcinoma 30.2 APC CTNNB1 KRAS MLH1
36 familial colorectal cancer 30.1 APC MLH1 MSH2
37 gastric cancer 30.1 APC CCND1 CTNNB1 KRAS MLH1 MSH2
38 colorectal adenocarcinoma 30.0 CTNNB1 KRAS MLH1 MSH2
39 thyroid carcinoma, familial medullary 30.0 KRAS MEN1 RET
40 hyperplastic polyposis syndrome 30.0 APC KRAS
41 familial isolated hyperparathyroidism 29.9 CDC73 MEN1 RET
42 fibrous dysplasia 29.9 APC GNAS PRL
43 gastric adenocarcinoma 29.8 APC CCND1 CTNNB1 GNAS KRAS MLH1
44 intestinal disease 29.8 CCND1 CTNNB1 KRAS MLH1 MSH2
45 bladder urothelial carcinoma 29.8 CCND1 CTNNB1 KRAS MLH1
46 differentiated thyroid carcinoma 29.8 KRAS RET TSHR
47 hepatoblastoma 29.6 APC CTNNB1 PLAG1
48 rectal neoplasm 29.5 KRAS MLH1 MSH2
49 attenuated familial adenomatous polyposis 29.5 APC MSH2
50 anal fistula 29.5 MLH1 MSH2

Graphical network of the top 20 diseases related to Adenoma:



Diseases related to Adenoma

Symptoms & Phenotypes for Adenoma

GenomeRNAi Phenotypes related to Adenoma according to GeneCards Suite gene sharing:

26 (show top 50) (show all 58)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-107 10.86 SMAD4
2 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.86 CTNNB1 KRAS SMAD4
3 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.86 PLAGL2
4 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.86 CTNNB1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.86 MEN1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.86 KRAS
7 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.86 MEN1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-124 10.86 MLH1 PLAG1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.86 CCND1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.86 PLAGL2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-128 10.86 MEN1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-130 10.86 MLH1 RET
13 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10.86 RET
14 Increased shRNA abundance (Z-score > 2) GR00366-A-133 10.86 APC
15 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.86 MLH1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.86 PLAGL2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.86 PLAG1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.86 CCND1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.86 CCND1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.86 CCND1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.86 RET
22 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.86 KRAS
23 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.86 RET
24 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.86 APC CCND1 CTNNB1 KRAS MEN1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-192 10.86 APC
26 Increased shRNA abundance (Z-score > 2) GR00366-A-195 10.86 MLH1 SMAD4
27 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.86 KRAS
28 Increased shRNA abundance (Z-score > 2) GR00366-A-197 10.86 CTNNB1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.86 CCND1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.86 APC
31 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.86 PLAG1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.86 CCND1 SMAD4
33 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.86 CCND1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.86 KRAS
35 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.86 CCND1 SMAD4 PLAGL2 RET
36 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.86 APC
37 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.86 CCND1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.86 SMAD4
39 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.86 MEN1 SMAD4
40 Increased shRNA abundance (Z-score > 2) GR00366-A-46 10.86 SMAD4
41 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.86 CTNNB1 MEN1
42 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.86 APC CTNNB1 KRAS MEN1 PLAG1
43 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.86 KRAS
44 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.86 RET
45 Increased shRNA abundance (Z-score > 2) GR00366-A-54 10.86 SMAD4
46 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.86 KRAS PLAGL2 PLAG1
47 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.86 CTNNB1
48 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.86 CTNNB1 SMAD4 PLAGL2 RET
49 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.86 APC CTNNB1 MLH1 SMAD4
50 Increased shRNA abundance (Z-score > 2) GR00366-A-78 10.86 MLH1

MGI Mouse Phenotypes related to Adenoma:

46 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.49 AIP APC CCND1 CDC73 CTNNB1 GNAS
2 endocrine/exocrine gland MP:0005379 10.46 AIP APC CCND1 CDC73 CTNNB1 GNAS
3 growth/size/body region MP:0005378 10.45 AIP APC CCND1 CDC73 CTNNB1 GNAS
4 homeostasis/metabolism MP:0005376 10.45 AIP APC CCND1 CDC73 CTNNB1 GNAS
5 digestive/alimentary MP:0005381 10.39 APC CCND1 CDC73 CTNNB1 KRAS LHCGR
6 cardiovascular system MP:0005385 10.38 AIP APC CCND1 CDC73 CTNNB1 GNAS
7 immune system MP:0005387 10.36 APC CCND1 CDC73 CTNNB1 GNAS KRAS
8 behavior/neurological MP:0005386 10.35 APC CCND1 CDC73 CTNNB1 GNAS KRAS
9 mortality/aging MP:0010768 10.34 AIP APC CCND1 CDC73 CTNNB1 GNAS
10 hematopoietic system MP:0005397 10.31 APC CCND1 CDC73 CTNNB1 GNAS KRAS
11 embryo MP:0005380 10.27 AIP APC CDC73 CTNNB1 KRAS MEN1
12 integument MP:0010771 10.27 AIP APC CCND1 CDC73 CTNNB1 GNAS
13 neoplasm MP:0002006 10.21 AIP APC CCND1 CDC73 CTNNB1 GNAS
14 craniofacial MP:0005382 10.19 APC CCND1 CDC73 CTNNB1 GNAS KRAS
15 nervous system MP:0003631 10.17 APC CCND1 CDC73 CTNNB1 GNAS KRAS
16 liver/biliary system MP:0005370 10.16 AIP APC CDC73 CTNNB1 GNAS KRAS
17 limbs/digits/tail MP:0005371 10.13 APC CTNNB1 GNAS KRAS LHCGR PLAGL1
18 muscle MP:0005369 10.01 APC CDC73 CTNNB1 GNAS KRAS MEN1
19 reproductive system MP:0005389 9.97 APC CCND1 CDC73 CTNNB1 KRAS LHCGR
20 renal/urinary system MP:0005367 9.86 APC CDC73 CTNNB1 GNAS KRAS LHCGR
21 respiratory system MP:0005388 9.61 CCND1 CDC73 CTNNB1 GNAS KRAS LHCGR
22 skeleton MP:0005390 9.32 APC CCND1 CDC73 CTNNB1 GNAS KRAS

Drugs & Therapeutics for Adenoma

Drugs for Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 578)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
2
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560
3
Ticlopidine Approved Phase 4 55142-85-3 5472
4
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-78-2 2244
5
Pantoprazole Approved Phase 4,Not Applicable 102625-70-7 4679
6
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
7
Magnesium citrate Approved Phase 4,Phase 3,Phase 2 3344-18-1
8
Magnesium oxide Approved Phase 4,Phase 2 1309-48-4 14792
9
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 329-65-7 838
10
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 51-43-4 5816
11
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-03-3
12
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-23-7 5754
13
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
14
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83150-76-9 383414 6400441
15
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 557795-19-4, 341031-54-7 5329102
16
Metformin Approved Phase 4,Phase 2,Phase 1,Not Applicable 657-24-9 14219 4091
17
Somatostatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 51110-01-1, 38916-34-6 53481605
18
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
19
Cabergoline Approved Phase 4,Phase 3,Phase 2,Not Applicable 81409-90-7 54746
20
leucovorin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-05-9 6006 143
21
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
22
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
23
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
24
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
25
Pasireotide Approved Phase 4,Phase 2,Phase 3,Phase 1 396091-73-9 9941444
26
Sodium sulfate Approved, Vet_approved Phase 4,Phase 3,Phase 2 7757-82-6
27
Bisacodyl Approved Phase 4,Phase 3,Phase 2,Not Applicable 603-50-9
28
Zinc Approved, Investigational Phase 4,Phase 3 7440-66-6
29
Liraglutide Approved Phase 4 204656-20-2 44147092
30
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 1 93-14-1 3516
31
Simethicone Approved Phase 4,Phase 3,Not Applicable 8050-81-5
32
Methylene blue Approved, Investigational Phase 4,Phase 3 61-73-4
33 lanreotide Approved Phase 4,Phase 3,Phase 2 108736-35-2
34
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
35
Cefdinir Approved Phase 4 91832-40-5 6915944
36
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
37
Cefuroxime Approved Phase 4 55268-75-2 5361202 5479529
38
Cefazolin Approved Phase 4 25953-19-9 656510 33255
39
Sulfamethoxazole Approved Phase 4 723-46-6 5329
40
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
41
Codeine Approved, Illicit Phase 4 76-57-3 5284371
42
Acetaminophen Approved Phase 4,Phase 1 103-90-2 1983
43
Clarithromycin Approved Phase 4,Not Applicable 81103-11-9 84029
44
Dyclonine Approved Phase 4 586-60-7 3180
45
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 77-92-9 311
46
Vitamin C Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 50-81-7 5785 54670067
47
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 59-30-3 6037
48
Ecabet Investigational Phase 4 86408-72-2, 33159-27-2 65781
49
Lactitol Investigational Phase 4 585-86-4 3871
50 Adjuvants, Anesthesia Phase 4,Phase 3,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 1345)
# Name Status NCT ID Phase Drugs
1 Does the Hyoscine N-Butylbromide Administered During Colonoscopy Increase the Adenoma Detection Rate? Unknown status NCT01609855 Phase 4 Hyoscine Butyl Bromide 20mg/2 ml i.v.;Saline 2 ml i.v.
2 Efficacy Combined Fecal Immunochemical Test-Sigmoidoscopy for the Detection of Advanced Colorectal Neoplasia Unknown status NCT01767870 Phase 4
3 Prophylactic Pancreatic Duct Stent Placement After ESP of Major Papillary Tumors; Prospective, Randomized Study Unknown status NCT01737463 Phase 4
4 Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD. Unknown status NCT02638584 Phase 4 Ilaprazole;Rabeprazole
5 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adjusted Version Unknown status NCT02354560 Phase 4 Erythromycin
6 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Unknown status NCT02175914 Phase 4 Erythromycin
7 Participation and Detection Rate Diagnostic of a Colorectal Cancer Screening Program: CT Colonography vs. Flexible Sigmoidoscopy Unknown status NCT01739608 Phase 4
8 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
9 Efficacy of Ecabet Sodium and Proton Pump Inhibitor Combination Therapy in the Treatment of Iatrogenic Ulcer After Endoscopic Submucosal Dissection Unknown status NCT01308177 Phase 4 Ecabet
10 Efficacy and Safety of Split-dose Citrafleet Administered From 2 to 6 Hours Before Morning Colonoscopies Unknown status NCT01481714 Phase 4 Sodium picosulphate, magnesium oxid and citric acid;Sodium picosulphate/magnesium oxide and citric acid
11 Influence of Synacthen Infusion on the Results of Adrenal Venous Sampling in Patient With Primary Aldosteronism Unknown status NCT02127840 Phase 4 Synacthen infusion during adrenal venous sampling
12 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
13 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Unknown status NCT02759718 Phase 4
14 Endoscopy Nurse Participation in Adenoma Detection Rate During Colonoscopy Completed NCT01124266 Phase 4
15 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
16 Comparative Efficacy of Water & Indigo Carmine vs. Water or Air Method on Adenoma Detection Rate (ADR) - a Randomized Controlled Trial (RCT) Completed NCT01607255 Phase 4 Indigo carmine
17 Effect of Gum Chewing on Bowel Cleansing Before Colonoscopy Completed NCT02507037 Phase 4 polyethylene glycol
18 Glucagon and Colonoscopy Completed NCT02078726 Phase 4 Glucagon;Placebo
19 Preoperative Octreotide Treatment of Acromegaly Completed NCT00521300 Phase 4 Octreotide
20 A Multi-centre Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate) Completed NCT01689792 Phase 4 MOVIPREP;CitraFleet
21 Octreotide Efficacy and Safety in First-line Acromegalic Patients Completed NCT00171886 Phase 4 Octreotide
22 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Completed NCT01525550 Phase 4 sunitinib
23 Holmium Laser Enucleation of Prostate(HOLEP) vs Greenlight(XPS) Laser Photoselective Vapo-Enucleation of Prostate(PVEP) Completed NCT01494337 Phase 4
24 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
25 Evaluation of the Effects of Different Prostate Surgeries on Urinary and Sexual Function Completed NCT01810068 Phase 4
26 Colon Cleansing Quality of Polyethylene Glycol Compared With Polyethylene Glycol Plus Ascorbic Acid. Completed NCT02073552 Phase 4 Polyethylene glycol 4000;Macrogol 3350 plus ascorbic acid
27 Efficacy of 2-Liter Mixed Preparation With Bisacodyl Plus Polyethylene Glycol and 4-Liter Polyethylene Glycol for Colon Cleansing in Patients With Prior History of Colorectal Resection Completed NCT01887158 Phase 4 Polyethylene glycol;Bisacodyl
28 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Completed NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
29 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
30 Oral Sulfate Solution (SUPREP) Versus Polyethylene Glycol (PEG) Plus Ascorbic Acid Completed NCT02761213 Phase 4 Oral sulfate solution (OSS);2-L PEG/Asc
31 Comparative Study of Postprocessing Imaging Systems for Diminutive Colonic Polyps Completed NCT01133041 Phase 4
32 Evaluation of Colonoscopy With a Specific Device for the Detection of Adenomas Recruiting NCT03436004 Phase 4
33 Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding Recruiting NCT02032784 Phase 4 octreotide
34 Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
35 Comparative Effectiveness of Split-Dose Colonoscopy Bowel Preparation Regimens Recruiting NCT03298945 Phase 4 Miralax-Gatorade Prep;Golytely
36 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Recruiting NCT02842749 Phase 4 everolimus
37 Minimizing Narcotic Analgesics After Endocrine Surgery Recruiting NCT03469310 Phase 4 Acetaminophen 500Mg Cap;Tylenol #3 Oral Tablet;Tramadol
38 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
39 Effect of H. Pylori Eradication on the Fate of H. Pylori-associated Gastric Polyp Recruiting NCT03065868 Phase 4 H. pylori eradication (Amoxaxillin, Lanston, Clarithromycin)
40 Effect of Simethicone on Screening Colonoscopy Active, not recruiting NCT03119168 Phase 4 Simethicone Solution
41 Study Comparing the Bowel Cleansing Efficacy of PLENVU® Versus SELG-ESSE® Using a 2-Day Split Dosing Regimen. Active, not recruiting NCT03742232 Phase 4 PEG3350;Macrogol 4000
42 GreenLight Laser Photoselective Vaporization of the Prostate vs Plasma Kinetic Vaporization of the Prostate; RCT Active, not recruiting NCT02283684 Phase 4
43 A Comparison of Eleview Versus Hetastarch as Injectate for EMR Active, not recruiting NCT03350217 Phase 4 Eleview;Hetastarch
44 Comparison Between 3-L and 4-L Polyethylene Glycol in Bowel Preparation Not yet recruiting NCT03356015 Phase 4 4L Polyethylene Glycol;3L Polyethylene Glycol
45 Premedication Dyclonine Improves Visibility During Bowel Cleansing for Colonoscopy Not yet recruiting NCT03352700 Phase 4 3L PEG;3L PEG+Dyclonine Hydrochloride Mucilage
46 Impact of Reinforced Education by Wechat and Short Message Service on the Quality of Bowel Preparation Not yet recruiting NCT02832869 Phase 4
47 A Randomized Controlled Trial of Tailored Bowel Preparation Based on A Predictive Model Not yet recruiting NCT03704571 Phase 4 Polyethylene Glycol
48 Clinical Study on Prevention Colorectal Adenomatous Polyp Recurrence After Polypectomy Under Colonoscopy by Xiaoai Jiedu Decoction Not yet recruiting NCT03616444 Phase 4 Xiaoai Jiedu Decoction
49 Dose Individualization of Pemetrexed - IMPROVE-III Not yet recruiting NCT03655834 Phase 4 Pemetrexed
50 Dose Individualization of Pemetrexed - IMPROVE-II Not yet recruiting NCT03655821 Phase 4 Pemetrexed

Search NIH Clinical Center for Adenoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Adenoma

Anatomical Context for Adenoma

MalaCards organs/tissues related to Adenoma:

41
Pituitary, Colon, Thyroid, Prostate, Salivary Gland, Testes, Lung

Publications for Adenoma

Articles related to Adenoma:

(show top 50) (show all 8828)
# Title Authors Year
1
Massive hepatic adenoma response to bland embolization: A case study. ( 30338010 )
2019
2
Ultrasound Imaging of Hepatocellular Adenoma Using the New Histology Classification. ( 30396597 )
2019
3
Inhibition of Notch signaling attenuates pituitary adenoma growth in Nude mice. ( 30121620 )
2019
4
Optimal colonoscopy surveillance interval period for the adenoma patients who had an adequate polypectomy at baseline colonoscopy. ( 29481338 )
2019
5
Lipid-poor adrenal adenoma versus metastasis in lung cancer: Diagnosis by "comparative enhancement" at multiphasic MR imaging. ( 29970786 )
2018
6
Primary carcinoma ex-pleomorphic adenoma of anterior commissure of the larynx. ( 29980410 )
2018
7
Family history of colorectal cancer in first-degree relatives and metachronous colorectal adenoma. ( 29463834 )
2018
8
Testosterone- and Cortisol-secreting Oncocytic Adrenocortical Adenoma in the Pediatric Age-group. ( 29426273 )
2018
9
Cripto-1 is overexpressed in carcinoma ex pleomorphic adenoma of salivary gland. ( 29594385 )
2018
10
Superficially Spreading Signet-Ring Cell Carcinoma Perpendicularly Colliding with Gastric Adenoma: a Rare Case Report. ( 29441461 )
2018
11
Lacrimal gland pleomorphic adenoma and malignant epithelial tumours: clinical and imaging differences. ( 29680804 )
2018
12
Associations of Circulating 25-Hydroxyvitamin D3 Concentrations With Incident, Sporadic Colorectal Adenoma Risk According to Common Vitamin D Binding Protein Isoforms. ( 29788105 )
2018
13
A Migratory Mishap: Giant Mediastinal Parathyroid Adenoma. ( 29360437 )
2018
14
Left-Sided Colectomy: One of the Important Risk Factors of Metachronous Colorectal Adenoma After Colectomy for Colon Cancer. ( 29417332 )
2018
15
Histopathologic Features of Colorectal Adenoma and Adenocarcinoma Developing Within Inflammatory Polyps in Miniature Dachshunds. ( 29852840 )
2018
16
Age and gender may be the key points in hyperglycemic patients with Helicobacter pylori infection combined colorectal adenoma-author's reply. ( 29644785 )
2018
17
Improved adenoma detection with Endocuff Vision: the ADENOMA randomised controlled trial. ( 29363535 )
2018
18
Frequency of Mismatch Repair Protein Deficiency in a Puerto Rican Population with Colonic Adenoma and Adenocarcinoma. ( 29976631 )
2018
19
Top 100 Most-Cited Articles on Pituitary Adenoma: A Bibliometric Analysis. ( 29870843 )
2018
20
KCNJ5 mutation as a predictor for resolution of hypertension after surgical treatment of aldosterone-producing adenoma. ( 29016532 )
2018
21
Associations of mitochondrial polymorphisms with sporadic colorectal adenoma. ( 29323753 )
2018
22
Identification, isolation and characterization of human LGR5-positive colon adenoma cells. ( 29467240 )
2018
23
Association of retinal nerve fibre layer thickness with quantitative magnetic resonance imaging data of the optic chiasm in pituitary adenoma patients. ( 29398198 )
2018
24
Association between investigator-measured body-mass index and colorectal adenoma: a systematic review and meta-analysis of 168,201 subjects. ( 29288474 )
2018
25
Clinical and pathological characteristics predicted the postoperative recurrence and progression of pituitary adenoma: a retrospective study with 10 years follow-up. ( 29981466 )
2018
26
Consensus-driven in-hospital cortisol assessment after ACTH-secreting pituitary adenoma resection. ( 29143885 )
2018
27
Massive pleural and pericardial effusion due to hypothyroidism in a patient with a surgically treated thyroid-stimulating hormone-producing pituitary adenoma. ( 29757110 )
2018
28
Triptolide inhibits pituitary adenoma cell viability, migration and invasion via ADAM12/EGFR signaling pathway. ( 29288766 )
2018
29
Emergence of Pituitary Adenoma in a Child during Surveillance: Clinical Challenges and the Family Members' View in an <i>AIP</i> Mutation-Positive Family. ( 29849625 )
2018
30
Screening of biomarkers for liver adenoma in low-dose-rate gamma-ray-irradiated mice. ( 29424599 )
2018
31
Effect of Xylosyltransferase-I Silencing on Implanting Growth of Salivary Pleomorphic Adenoma. ( 29867072 )
2018
32
Dynamic CT for Parathyroid Adenoma Detection: How Does Radiation Dose Compare With Nuclear Medicine? ( 29629803 )
2018
33
A rare case of atypical pleomorphic adenoma arising from periocular ectopic lacrimal gland. ( 29936687 )
2018
34
Endoanal resection of a giant villous adenoma in the middle rectum - Video Vignette. ( 29364560 )
2018
35
Visfatin levels in hormonally inactive adrenal adenoma and their association with metabolic parameters ( 29914251 )
2018
36
Giant pituitary adenoma: histological types, clinical features and therapeutic approaches. ( 29909598 )
2018
37
Pleomorphic adenoma of salivary glands: common and uncommon CT and MR imaging features. ( 29845358 )
2018
38
Artificial neural network model to distinguish follicular adenoma from follicular carcinoma on fine needle aspiration of thyroid. ( 29266871 )
2018
39
Pleomorphic adenoma of the lacrimal gland: A review with updates on malignant transformation and molecular genetics. ( 29755265 )
2018
40
Promoter hypermethylation may contribute to Ea89cadherin repression in the human salivary carcinoma ex pleomorphic adenoma. ( 29207084 )
2018
41
Ceruminous adenoma mimicking otitis externa. ( 29796271 )
2018
42
Age and gender may be the key points in hyperglycemic patients with Helicobacter pylori infection combined colorectal adenoma. ( 29480547 )
2018
43
Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. ( 29279316 )
2018
44
The B-ADENOMA Study: Bowelscope - Accuracy of Detection using Endocuff Optimisation of Mucosal Abnormalities: Study Protocol for randomised controlled trial. ( 29978008 )
2018
45
Secreting ectopic adrenal adenoma: A rare condition to be aware of. ( 29525561 )
2018
46
Different effects of metformin and insulin on primary and secondary chemoprevention of colorectal adenoma in diabetes type 2: Traditional and Bayesian meta-analysis. ( 29383018 )
2018
47
Localization of Parathyroid Adenoma Using Contrast-Enhanced Sonography. ( 29781147 )
2018
48
The Fatty Liver Index: A Simple and Accurate Predictor of Colorectal Adenoma in an Average-Risk Population. ( 29219920 )
2018
49
Complications after superficial parotidectomy for pleomorphic adenoma. ( 29924764 )
2018
50
A Novel Technology for Localization of Parathyroid Adenoma: Ultrasound-Guided Fine Needle Aspiration Combined With Rapid Parathyroid Hormone Detection and Nano-Carbon Technology. ( 29890904 )
2018